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show that opioid use in treatment and control groups was not statistically different. Midazolam use was discontinued in our nursery early in the study because of concerns about side effects. Prior to that decision, there was no statistically significant difference in its use in our treatment and control groups. Thus, the correspondents' concern that differential use of these agents might explain the decreased use of chloral hydrate in our most severely ill patients is not supported by the data.
The use of behavioral and physiologic markers of stress and agitation is widely accepted. The use of these parameters by one of the correspondents in her own research speaks for itself. 2 The role of developmental care in reducing these behaviors and in enhancing behavioral organization is nicely reviewed by Als.
3 A number of behavioral and physiologic manifestations of stress and agitation are incorporated into the assessments that are an integral part of the developmental care program. These include color changes and variations in heart rate and respiratory patterns, some of which can be categorized as apnea and bradycardia. We continue to hold that it is plausible-and not simplistic-that apnea and bradycardia can be physiologic markers of stress and agitation. We evaluated the frequency of apnea and bradycardia from nursing flow sheets to provide additional assurance that the treatment patients were not being undersedated. This seems unlikely, in any case, given their otherwise favorable medical and behavioral outcomes.
Based on the above, and as we discussed,
